Compounds which potentiate glutamate receptor and uses thereof in medicine
    5.
    发明授权
    Compounds which potentiate glutamate receptor and uses thereof in medicine 失效
    增强谷氨酸受体的药物及其在药物中的应用

    公开(公告)号:US07572819B2

    公开(公告)日:2009-08-11

    申请号:US11673044

    申请日:2007-02-09

    IPC分类号: A61K31/445 C07D213/56

    摘要: Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; each R4, which may be the same or different, is C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, monoC1-4alkylamino or diC1-4alkylamino; p is 0, 1 or 2; n is 1 or 2; R5 and R6, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consisting of C1-6alkyl, C1-6alkoxy, acetyl, halogen, haloC1-6alkyl, cyano, nitro, amino, monoC1-4alkylamino and diC1-4alkylamino. Methods of preparation of the compounds, and uses thereof in medicine, for example treatment of schizophrenia, are also disclosed.

    摘要翻译: 公开了式(I)化合物或其药学上可接受的盐,溶剂合物或前体药物:其中R 1是C 1-6烷基,卤代C 1-6烷基,C 2-6烯基,氨基,单C 1-4烷基氨基或二C 1-4烷基氨基; R 2和R 3可以相同或不同,为氢,卤素,C 1-6烷基,卤代C 1-6烷基,C 1-4烷氧基,卤代C 1-4烷氧基,氰基,氨基,单C 1-4烷基氨基或二C 1-4烷基氨基; 每个R 4可以相同或不同,为C 1-6烷基,卤素,C 1-6烷基,卤代C 1-6烷基,C 1-4烷氧基,卤代C 1-4烷氧基,氰基,硝基,氨基,单C 1-4烷基氨基或二C 1-4烷基氨基; p为0,1或2; n为1或2; R 5和R 6可以相同或不同,为氢,卤素,C 1-6烷基,卤代C 1-6烷基,C 1-4烷氧基,卤代C 1-4烷氧基,氰基,氨基,单C 1-4烷基氨基或二C 1-4烷基氨基; 并且Het是噻吩基,吡啶基,嘧啶基,哒嗪基,嘧啶基,吡嗪基,咪唑基,吡唑基,吡咯基,喹啉基,噻唑基或呋喃基,其各自可以被一个或多个独立地选自C 1-6烷基, 1-6烷氧基,乙酰基,卤素,卤代C 1-6烷基,氰基,硝基,氨基,单C 1-4烷基氨基和二C 1-4烷基氨基。 还公开了化合物的制备方法及其在药物中的用途,例如精神分裂症的治疗。

    Compounds which potentiate glutamate receptor and uses thereof in medicine

    公开(公告)号:US07618969B2

    公开(公告)日:2009-11-17

    申请号:US11573370

    申请日:2005-08-05

    IPC分类号: A61K31/44 C07D213/02

    摘要: Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; each R4, which may be the same or different, is C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, monoC1-4alkylamino or diC1-4alkylamino; p is 0, 1 or 2; n is 1 or 2; R5 and R6, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consisting of C1-6alkyl, C1-6alkoxy, acetyl, halogen, haloC1-6alkyl, cyano, nitro, amino, monoC1-4alkylamino and diC1-4alkylamino. Methods of preparation of the compounds, and uses thereof in medicine, for example treatment of schizophrenia, are also disclosed.

    COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE

    公开(公告)号:US20080194648A1

    公开(公告)日:2008-08-14

    申请号:US11673044

    申请日:2007-02-09

    摘要: Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; each R4, which may be the same or different, is C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, monoC1-4alkylamino or diC1-4alkylamino; p is 0, 1 or 2; n is 1 or 2; R5 and R6, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consisting of C1-6alkyl, C1-6alkoxy, acetyl, halogen, haloC1-6alkyl, cyano, nitro, amino, monoC1-4alkylamino and diC1-4alkylamino. Methods of preparation of the compounds, and uses thereof in medicine, for example treatment of schizophrenia, are also disclosed.